In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance

Osama AA Ahmed,1,2 Shaimaa M Badr-Eldin1,3 1Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 3Department of Pharmaceutics and Indus...

Full description

Bibliographic Details
Main Authors: Ahmed OAA, Badr-Eldin SM
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:International Journal of Nanomedicine
Subjects:
Online Access:https://www.dovepress.com/in-situ-misemgel-as-a-multifunctional-dual-absorption-platform-for-nas-peer-reviewed-article-IJN
id doaj-997b150728a941d69afb99c9aeaeafb8
record_format Article
spelling doaj-997b150728a941d69afb99c9aeaeafb82020-11-24T21:42:09ZengDove Medical PressInternational Journal of Nanomedicine1178-20132018-10-01Volume 136325633541388In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performanceAhmed OAABadr-Eldin SMOsama AA Ahmed,1,2 Shaimaa M Badr-Eldin1,3 1Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt Background: Raloxifene hydrochloride (RLX) is approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis, in addition to reducing the risk of breast cancer in postmenopausal women. RLX has the disadvantages of low aqueous solubility, extensive presystemic intestinal glucuronidation, and first-pass metabolism, resulting in a limited bioavailability of only 2%. The aim of this work was to enhance the bioavailability of RLX via the formulation of an in situ nasal matrix (misemgel) comprising micelles made of vitamin E and D-α-tocopheryl polyethylene glycol 1000 succinate and nanosized self-emulsifying systems (NSEMS). Materials and methods: Optimization of the RLX-loaded NSEMS was performed using a mixture design. The formulations were characterized by particle size and then incorporated into an in situ nasal gel. Transmission electron microscopy, bovine nasal mucosa ex vivo permeation, and visualization using a fluorescence laser microscope were carried out on the RLX in situ misemgel comparing with raw RLX in situ gel. In addition, the in vivo performance was studied in rats. Results: The results revealed improved permeation parameters for RLX misemgel compared with control gel, with an enhancement factor of 2.4. In vivo studies revealed a 4.79- and 13.42-fold increased bioavailability for RLX in situ misemgel compared with control RLX in situ gel and commercially available tablets, respectively. The obtained results highlighted the efficacy of combining two different formulations to enhance drug delivery and the benefits of utilizing different possible paths for drug absorption. Conclusion: The developed in situ misemgel matrix could be considered as a promising multifunctional platform for nasal delivery which works based on a dual-absorption mechanism. Keywords: micelles, nanosized self-emulsifying systems, mixture design, fluorescence laser microscope, permeation, pharmacokineticshttps://www.dovepress.com/in-situ-misemgel-as-a-multifunctional-dual-absorption-platform-for-nas-peer-reviewed-article-IJNmicellesnanosized self-nanoemulsifying systemmixture designfluorescence laser microscopepermeationpharmacokinetics
collection DOAJ
language English
format Article
sources DOAJ
author Ahmed OAA
Badr-Eldin SM
spellingShingle Ahmed OAA
Badr-Eldin SM
In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
International Journal of Nanomedicine
micelles
nanosized self-nanoemulsifying system
mixture design
fluorescence laser microscope
permeation
pharmacokinetics
author_facet Ahmed OAA
Badr-Eldin SM
author_sort Ahmed OAA
title In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
title_short In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
title_full In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
title_fullStr In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
title_full_unstemmed In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
title_sort in situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance
publisher Dove Medical Press
series International Journal of Nanomedicine
issn 1178-2013
publishDate 2018-10-01
description Osama AA Ahmed,1,2 Shaimaa M Badr-Eldin1,3 1Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt Background: Raloxifene hydrochloride (RLX) is approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis, in addition to reducing the risk of breast cancer in postmenopausal women. RLX has the disadvantages of low aqueous solubility, extensive presystemic intestinal glucuronidation, and first-pass metabolism, resulting in a limited bioavailability of only 2%. The aim of this work was to enhance the bioavailability of RLX via the formulation of an in situ nasal matrix (misemgel) comprising micelles made of vitamin E and D-α-tocopheryl polyethylene glycol 1000 succinate and nanosized self-emulsifying systems (NSEMS). Materials and methods: Optimization of the RLX-loaded NSEMS was performed using a mixture design. The formulations were characterized by particle size and then incorporated into an in situ nasal gel. Transmission electron microscopy, bovine nasal mucosa ex vivo permeation, and visualization using a fluorescence laser microscope were carried out on the RLX in situ misemgel comparing with raw RLX in situ gel. In addition, the in vivo performance was studied in rats. Results: The results revealed improved permeation parameters for RLX misemgel compared with control gel, with an enhancement factor of 2.4. In vivo studies revealed a 4.79- and 13.42-fold increased bioavailability for RLX in situ misemgel compared with control RLX in situ gel and commercially available tablets, respectively. The obtained results highlighted the efficacy of combining two different formulations to enhance drug delivery and the benefits of utilizing different possible paths for drug absorption. Conclusion: The developed in situ misemgel matrix could be considered as a promising multifunctional platform for nasal delivery which works based on a dual-absorption mechanism. Keywords: micelles, nanosized self-emulsifying systems, mixture design, fluorescence laser microscope, permeation, pharmacokinetics
topic micelles
nanosized self-nanoemulsifying system
mixture design
fluorescence laser microscope
permeation
pharmacokinetics
url https://www.dovepress.com/in-situ-misemgel-as-a-multifunctional-dual-absorption-platform-for-nas-peer-reviewed-article-IJN
work_keys_str_mv AT ahmedoaa insitumisemgelasamultifunctionaldualabsorptionplatformfornasaldeliveryofraloxifenehydrochlorideformulationcharacterizationandinvivoperformance
AT badreldinsm insitumisemgelasamultifunctionaldualabsorptionplatformfornasaldeliveryofraloxifenehydrochlorideformulationcharacterizationandinvivoperformance
_version_ 1716664052289110016